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Purpose:With growing evidence that inflammation and low muscularity play a role in the
survival of cancer patients, we evaluated the prognostic implications of sarcopenia with
systemic inflammation in patients who underwent definitive chemoradiotherapy (CCRT)
for locally advanced head and neck cancer.
Materials and Methods: We analyzed 221 patients with head and neck cancer
who received definitive CCRT between 2006 and 2015. The skeletal muscle area was
measured using a single computed tomography image slice at the level of the third lumbar
vertebra (L3). Sarcopenia was defined as an L3 muscle index of <49 cm2/m2 for men
and <31 cm2/m2 for women.
Results: Patients with sarcopenia (n = 106) exhibited higher neutrophil/lymphocyte
ratios (NLRs) than those without (n = 115); the former also had an inferior 3-year overall
survival (OS) rate (62%) than the latter (76%, p= 0.037). Among patients with sarcopenia,
those who also had high NLRs (n= 51) showed significantly poorer OS and progression-
free survival (PFS). In the multivariate analysis, sarcopenia plus a high NLR remained
the most significant predictor of poor OS and PFS. Patients with sarcopenia required
more frequent interruption of RT; patients whose RT was interrupted for≥5 days showed
inferior disease control and OS.
Conclusions: Sarcopenia accompanied by systemic inflammation at initial diagnosis is
associated with significantly inferior OS and PFS. Additionally, patients with sarcopenia
required RT interruption more frequently. Intensive nutritional support and additional
treatment methods are required for these patients while undergoing RT.
Keywords: sarcopenia, inflammation, head and neck cancer, chemoradiotherapy, survival
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INTRODUCTION
Patients with head and neck cancer may experience progressive
weight loss following their diagnosis; significant weight loss is
associated with poorer overall survival (OS) (1, 2). The prognoses
of these patients can be influenced in part by changes in body
composition and loss of body weight (3). Cancer cachexia is
related to the activation of systemic inflammatory responses
as well as imbalances in energy intake and expenditure over
the disease course and during treatment. During this process,
sarcopenia is the most commonly occurring condition (4, 5).
Sarcopenia, the loss of skeletal muscle mass, function, and
strength, has emerged as an important prognostic factor in
various types of cancer, including head and neck cancer
(6). It is associated with an older age, poor performance
status, malnutrition, and treatment-related toxicities. However,
emerging evidence suggests that sarcopenia is a prevalent
condition in cancer patients regardless of disease stage and
nutritional status and is associated with higher mortality rates
and/or poor disease control (7).
Meanwhile, numerous studies have suggested that systemic
inflammation is indicative of cancer aggressiveness and is
associated with poor prognoses. The neutrophil/lymphocyte ratio
(NLR) is widely used as a marker of systemic inflammation (8).
Patients with different types of cancer who exhibit elevated NLRs
show very poor disease control as well as inferior OS. Previous
studies have emphasized the role of systemic inflammation as a
driver of muscle degradation in cancer patients (9, 10). Patients
with colorectal cancer and high NLRs have a significantly lower
skeletal muscle index, and those with both high NLRs and
sarcopenia show inferior OS rates (11). Male patients with small
cell lung cancer and sarcopenia accompanied by high NLRs
were shown to have poorer prognoses and not tolerate standard
treatments (12).
Previous studies of sarcopenia in cancer patients focused on
the effect of surgery and/or chemotherapy; there are limited data
on the effect of sarcopenia combined with systemic inflammation
in patients with head and neck cancer who undergo definitive
chemoradiotherapy (CCRT), including CCRT-related toxicities
and tolerance. Therefore, we hypothesized that sarcopenia,
especially when accompanied by systemic inflammation, plays
a significant role in determining survival, disease control, and
treatment tolerance in patients undergoing CCRT for head and
neck cancer.
METHODS
Patients and Treatment Profiles
In a single-institutional retrospective study, we analyzed 272
patients with locally advanced (American Joint Committee on
Cancer [AJCC] stage III–IVB) head and neck cancer, including
cancer of the oral cavity, nasopharynx, oropharynx hypopharynx,
and larynx, who received definitive radiotherapy (RT) between
January 2006 and December 2015. Patients who had undergone
whole-body positron emission tomography (PET)-computed
tomography (CT) or abdominal CT at diagnosis were eligible
for the study. Those who had no CT data of sufficient quality
to perform accurate measurements of the tissue area at the
3rd lumbar level (L3) (n = 43) or no height data (n = 8)
were excluded; hence, our final cohort comprised 221 patients.
The body mass index (BMI) grouping based on the World
Health Organization criteria is as follows: BMI < 18.5 kg/m2
(underweight), BMI 18.5–25 kg/m2 (normal weight), BMI 25–
30 kg/m2 (overweight), and BMI ≥ 30 kg/m2 (obese). This study
was approved by the institutional review board of the Gangnam
Severance Hospital (protocol number 3-2017-0269).
Patients were treated with definitive RT alone, concurrent
chemoradiotherapy (CCRT), or induction chemotherapy
followed by CCRT depending on the primary tumor site, tumor
stage, risk factors, and/or the physicians’ decisions. External
beam RT was performed with 3D-conformal RT (54–70.2Gy) or
intensity-modulated RT (IMRT) (55.2–74.2Gy).
Measurement of Body Composition and
Definition of Sarcopenia
Because dual-energy X-ray absorptiometry (DXA) is infrequently
used in routine clinical practice, we used a previously validated
CT-based body composition method with scans acquired at the
initial diagnosis (i.e., whole-body PET-CT or abdominal CT).
For each CT scan, a single axial slice at the level of L3 was
selected. The MIM Vista software (MIM corp., Version 6.1, OH,
USA) was used to demarcate skeletal muscle, visceral fat tissue,
and subcutaneous fat tissue according to predefined validated
boundaries based on Hounsfield units (HUs). The following
thresholds were applied: −29 to +150 HU for skeletal muscle,
−150 to −50 HU for visceral fat tissue, and −190 to −30 HU
for subcutaneous fat tissue. Figure 1 represents the slices of
computed tomography (CT) images of patients with (A) and
without (B) sarcopenia who had similar body mass indices. The
radiation oncologist who performed these measurements was
blinded to the treatment outcomes of all patients to minimize
bias.
The cross-sectional area of muscle and fat tissue (in square
centimeters) was normalized to the square of height in meters
and reported as the skeletal muscle index (cm2/m2). According
to international consensus, sarcopenia is defined as an L3 muscle
index of below 55 cm2/m2 in men and below 39 cm2/m2 in
women (13). In this study of Korean patients, however, we
defined sarcopenia as an L3 muscle index of below 49 cm2/m2
for men and below 31 cm2/m2 for women, based on a previous
epidemiologic study using DXA and the regression equation,
L3muscle index of CT =
height − adjusted appendicular skeletal muscle mass in DXA (kg/m2)− 1.17
0.11
to convert the CT value (12, 14).
Markers of Systemic Inflammation
The patients’ blood counts were obtained prior to performing
diagnostic procedures or administering treatments. Our primary
determinant of systemic inflammation was the NLR obtained at
the initial diagnosis. Receiver Operating Characteristic (ROC)
curves were constructed for the NLR using OS as the primary
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FIGURE 1 | Slices of computed tomography (CT) images of patients with (A) and without (B) sarcopenia who had similar body mass indices. Skeletal muscle, visceral
adipose tissue, and subcutaneous adipose tissue were measured using the MIM Vista software (MIM corp., version 6.1, OH, USA).
endpoint. A high NLR was defined as ≥2.7 with an area under
the curve of 0.66, with a sensitivity of 57.9% and specificity of
72.8% (Supplementary Figure 1), according to a previous meta-
analysis of the NLR in head and neck cancer that revealed
cutoff values of the NLR for dichotomization ranging from
1.92 to 5 (median, 2.69) (8). Data on serum albumin levels,
which are of particular interest as a marker of both nutritional
status as well as systemic inflammation, were available for 218
participants.
Statistical Analysis
Categorical data were analyzed using the Fisher’s exact test
or χ2 analyses, while continuous data between groups were
compared using the Mann-Whitney-U-test. OS was defined
as the interval between diagnosis and death from any cause
or last follow-up. Progression-free survival (PFS) was defined
as the interval between diagnosis to the detection of first
progression, death from any cause, or last follow-up. The
Kaplan-Meier method and log-rank test were used to estimate
and compare OS and PFS rates. We obtained hazard ratios
(HRs) using the cumulative survivor function. Univariate
and multivariate analyses for OS and PFS were conducted
with the Cox proportional hazards model. We performed
multivariate Cox hazard regression analysis on the variables
that showed p < 0.05 in the univariate analysis. HRs and their
corresponding 95% confidence intervals (CIs) are reported. P
< 0.05 was considered statistically significant. All analyses were
performed with IBM SPSS version 20.0 (SPSS, Chicago, IL,
USA).
RESULTS
Patient and Treatment Characteristics
Between 2006 and 2015, a total of 221 patients with head and
neck cancer (74, 58, 50, 32, and 7 patients with nasopharyngeal,
oropharyngeal, hypopharyngeal, laryngeal, and oral cavity
cancer, respectively) received definitive RT (Table 1). Themedian
age at diagnosis was 59 years (range 18–94 years); 180 patients
(81.4%) were men and 41 (18.6%) women. Most patients
received CCRT (92.3%; of these, 71.9% underwent only CCRT
whereas 20.4% underwent induction chemotherapy followed by
CCRT), while only 7.7% received RT alone. The median BMI
was 22.6 kg/m2, and the mean NLR was 2.55 (range 0.78–
24.47).
Patients were divided into 2 groups (those with vs. those
without sarcopenia), based on the L3 muscle index cut-
off described in the Materials and Methods section. The
characteristics of the patients in the non-sarcopenia group (n =
115, 52%) and sarcopenia group (n = 106, 48%) are shown in
Table 1. Themedian skeletal muscle indices were 46.4 (range 4.9–
88.0), 51.1 (range 31.5–88.0), and 43.2 (range 4.93–48.9) in the
total cohort, non-sarcopenia, and sarcopenia group, respectively.
Patients in the sarcopenia group were older, predominantly male
(98.1%), and exhibited a poorer performance status and more
advanced T-stage disease than those in the non-sarcopenia group.
The proportion of patients who were underweight was higher
in the sarcopenia than in the non-sarcopenia group (17.0 vs.
4.3%, p < 0.001); patients in the sarcopenia group also had
lower visceral and subcutaneous fat indices. When considering
inflammatory markers, elevated white blood cell (WBC) counts
and absolute neutrophil counts (ANCs) were observed in patients
with sarcopenia; moreover, the NLR tended to be higher in this
group (mean: 3.5 vs. 2.86, p= 0.053). Serum albumin levels were
similar in both groups.
Treatment Profile and Toxicity Analysis
Most patients received CCRT (n = 204, 92.3%), and 82.4%
underwent IMRT. More than half of the patients received a
radiation dose of 70Gy or higher. The treatment schemes, RT
modalities, RT doses, and fraction sizes were not significantly
different between the 2 groups (Table 2), nor were the total RT
times (49 vs. 51 days, p = 0.686) or treatment completion rates.
Frontiers in Oncology | www.frontiersin.org 3 October 2018 | Volume 8 | Article 457
Cho et al. Impact of Sarcopenia on Chemoradiotherapy
TABLE 1 | Patient characteristics.
Total Non-sarcopenia Sarcopenia p-value
Characteristics N = 221 % N = 115 % N = 106 %
Age Median 59 56 64 0.01
(Range) 18–94 18–86 18–94
Sex Male 180 81.4 76 66.1 104 98.1 <0.001
Female 41 18.6 39 33.9 2 1.9
aECOG PS 0.1 177 80.1 106 92.2 71 67.0 <0.001
≥2 44 19.9 9 7.8 35 33.0
Primary site Nasopharynx 74 33.5 41 35.7 33 31.1 0.443
Oropharynx 58 26.2 33 28.7 25 23.6
Hypopharynx 50 22.6 22 19.1 28 26.4
Larynx 32 14.5 17 14.8 15 14.2
Oral cavity 7 3.2 2 1.7 5 4.7
T stage T1 27 12.2 16 13.9 11 10.4 0.034
T2 48 21.7 29 25.2 19 17.9
T3 63 28.5 23 20.0 40 37.7
T4 83 37.6 47 40.9 36 34.0
N stage N0 35 15.8 17 14.8 18 17.0 0.958
N1 30 13.6 15 13.0 15 14.2
N2 145 65.6 77 67.0 68 64.2
N3 11 5.0 6 5.2 5 4.7
bAJCC stage III 70 31.7 33 28.7 37 34.9 0.321
IVA/B 151 68.3 82 71.3 69 65.1
cBMI Underweight 23 10.4 5 4.3 18 17.0 <0.001
Normal weight 153 69.2 77 67.0 76 71.7
Overweight 42 19.0 30 26.1 12 11.3
Obese 3 1.4 3 2.6 0 0.0
dSMI Median 46.4 51.1 43.2 <0.001
(cm2/m2) (Range) 4.9–88.0 31.5–88.0 4.93–48.9
eVFI Median 79.5 86.1 70.8 0.089
(cm2/m2) (Range) 0.5–305.8 3.3–305.8 0.5–301.3
fSFI Median 91.7 106.8 71.4 <0.001
(cm2/m2) (Range) 0.4–289.0 8.3–271.4 0.4–289.0
Hemoglobin Mean 13.7 13.8 13.4 0.045
(g/dL) (Range) 7.5–17.1 8.6–17.1 7.5–16.5
gWBC Mean 7 7.1 7.9 0.023
(x103 cells/µL) (Range) 3.0–22.3 3.3–13.4 3.0–22.3
hANC Mean 4.5 4.6 5.3 0.023
(x103 cells/ µL ) (Range) 1.4–20.7 1.6–11.3 1.4–20.7
iNLR Mean 2.55 2.86 3.5 0.053
(Range) 0.78–24.47 0.84–11.06 0.78–24.47
Platelets Mean 254 265 267 0.88
(x103 cells/µL) (Range) 40–563 82–526 40–563
Albumin Mean 4.3 4.3 4.2 0.108
(g/dL) (Range) 3.0–5.1 3.0–5.1 3.1–4.8
aECOG PS, Eastern Cooperative Oncology Group performance status.
bAJCC, American Joint Committee on Cancer.
cBMI, body mass index.
dSMI, skeletal muscle index.
eVFI, visceral fat index.
fSFI, subcutaneous fat index.
gWBC, white blood cell count.
hANC, absolute neutrophil count.
iNLR, neutrophil/lymphocyte ratio.
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TABLE 2 | Treatment profile and toxicity analysis.
Total Non-sarcopenia Sarcopenia p-value
Characteristics N = 221 % N = 115 % N = 106 %
Treatment scheme aRT alone 17 7.7 6 5.2 11 10.4 0.286
bCCRT 159 71.9 83 72.2 76 71.7
Induction + CCRT 45 20.4 26 22.6 19 17.9
RT modality c3D-CRT 39 17.6 18 15.7 21 19.8 0.418
d IMRT 182 82.4 97 84.3 85 80.2
RT dose <70Gy 96 43.4 47 40.9 49 46.2 0.422
(eEQD2, α/β = 3) ≥70Gy 125 56.6 68 59.1 57 53.8
Fraction size <210 59 26.7 31 27.0 28 26.4 0.928
(cGy) ≥210 162 73.3 84 73.0 78 73.6
RT time Median 50 49 51 0.686
(days) (Range) (30–94) (30–71) (31–94)
Interruption of RT No 194 87.8 106 92.2 86 81.1 0.015
(≥5 days) Yes 27 12.2 9 7.8 20 18.9
Completion of RT No 10 4.5 6 5.2 4 3.8 0.75
Yes 211 95.5 109 94.8 102 96.2
Acute toxicity All 71 32.1 40 34.8 31 29.2 0.378
(fRTOG Grade≥3) gA/N/V 10 4.5 0 0.0 1 0.9 0.081
Dysphagia 3 1.4 1 0.9 2 1.9 0.863
Skin reaction 38 17.2 6 5.2 7 6.6 0.778
Oral mucositis 48 21.7 31 27.0 16 15.1 0.031
Pharyngitis 19 8.6 8 7.0 11 10.4 0.365
aRT, radiotherapy.
bCCRT, concurrent chemoradiotherapy.
c3D-CRT, 3-dimensional conformal radiotherapy.
d IMRT, intensity-modulated radiotherapy.
eEQD2: equivalent dose in 2Gy.
fRTOG, Radiation Therapy Oncology Group.
gA/N/V, anorexia/nausea/vomiting.
However, RT interruption of ≥5 days was more frequent in the
sarcopenia than in the non-sarcopenia group (18.9 vs. 7.8%, p =
0.015).
Acute toxicity was evaluated according to the Radiation
Therapy Oncology Group toxicity grading criteria. Seventy-one
patients experienced grade (G) 3 acute toxicity, while none had
G4 or G5 acute toxicities. No patient exhibited ≥G3 fatigue, and
only 1 had G3 anorexia/nausea/vomiting. Dysphagia, dry mouth,
skin reaction, and pharyngitis were observed at similar rates in
both groups. However,≥G3 oral mucositis was more frequent in
the non-sarcopenia than in the sarcopenia group.
Analysis of Survival and Prognostic Factors
Seventy-one patients died over amedian follow-up duration of 30
months (range 1–110 months). Fifty-nine patients experienced
loco-regional failure, and 28 developed distant metastasis. The
3-year OS and PFS rates among all 221 patients were 69.6 and
52.9%, respectively. As shown in Figure 2A, patients in the
sarcopenia group showed poorer OS than those in the non-
sarcopenia group (3-year OS: 62 vs. 76%, p = 0.037); however,
PFS rates were not significantly different between the 2 groups
(3-year PFS: 46.6 vs. 55.6%, p= 0.187).
As sarcopenia is associated with cancer-related inflammation,
we assessed the effect of sarcopenia with inflammation on
survival using the NLR as a marker of systemic inflammation.
An of NLR ≥2.7 was defined as high; survival was compared
between patients with sarcopenia plus high NLR vs. others (those
with no sarcopenia or a low NLR). Patients with sarcopenia and
high NLRs exhibited significantly lower PFS (3-year PFS: 36.5
vs. 57.8%, p < 0.001) and poorer OS (3-year OS: 48 vs. 76%,
p < 0.001) (Figure 2B). Both locoregional failure and distant
metastasis were more frequently observed in the sarcopenia plus
high NLR group (64.7 vs. 39.4%, p < 0.001 and 58.8 vs. 30%, p <
0.001, respectively).
In the univariate analysis, sarcopenia, the NLR, and
sarcopenia plus a high NLR were significantly associated with
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FIGURE 2 | Kaplan-Meier curves comparing overall and progression-free survival between the sarcopenia and non-sarcopenia groups (A) as well as between patients
with sarcopenia plus a high neutrophil/lymphocyte ratio (NLR) and those without sarcopenia or a low NLR (B).
OS and PFS. As these 3 variables are highly correlated with
another, we first conducted a multivariate analysis including
the two variables sarcopenia and NLR. A high NLR but not
sarcopenia was significantly associated with poor OS (HR 2.240,
95% CI 1.344–3.732, p = 0.002) and PFS (HR 1.715, 95% CI
1.100–2.673, p <0.001). Second, we performed a multivariate
analysis using the variable “sarcopenia and NLR status,”; this
analysis showed that sarcopenia plus a high NLRwas a significant
prognostic factor for OS and PFS (OS: HR 2.785, 95% CI 1.674–
4.634, p < 0.001; PFS: HR 2.145, 95% CI 1.429–3.220, p <
0.001). Taken together, sarcopenia plus high NLR was the most
significant predictor of poor OS and PFS (Table 3). Older age
was a significant prognostic factor for OS, and a primary oral
cavity cancer and advanced stage were predictors of both poor
PFS and OS.
Neither the treatment scheme nor RT modality affected OS or
PFS. However, an RT interruption of ≥5 days adversely affected
both OS (HR 2.122, 95% CI 1.142–3.941, p = 0.017) and PFS
(HR 1.773, 95% CI 1.040–3.023, p = 0.035) independently in
the multivariate analysis (Table 3). Survival according to RT
interruption is presented in Figure 3.
DISCUSSION
In this study, patients with sarcopenia had poorer OS
than those without sarcopenia; furthermore, sarcopenia was
closely associated with PFS and OS when accompanied by
systemic inflammation. The presence of sarcopenia plus a high
NLR was the most significant independent predictor of PFS
and OS.
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FIGURE 3 | Overall and progression-free survival curves of patients requiring interruption of radiotherapy for <5 days vs. those requiring interruption for ≥5 days.
Sarcopenia alone did not decrease survival among our
patients. Although it was more frequently observed among
elderly patients, the development of sarcopenia may be
associated with conditions that are not exclusive to older
individuals. Cancer patients are generally subjected to several
cancer-specific and non-cancer-specific degenerative conditions
that result in decreased muscle mass and dysfunction; these
include malnutrition, physical inactivity, comorbidities, and
other factors directly related to disease pathophysiology and
therapy-related toxicity (15). Certain types of tumors induce
systemic inflammation; such cancer-related inflammation is
closely associated with the progression of sarcopenia (11, 12).
Patients with sarcopenia in this study exhibited increased levels
of inflammatory markers such as the WBC, ANC, and NLR; this
supports the notion that sarcopenia may reflect the increased
metabolic activity of more aggressive tumors, leading to systemic
inflammation and muscle wasting (16). Thus, we suggest that
sarcopenia accompanied by systemic inflammation represents a
more significant prognostic indicator.
Notably, patients with sarcopenia who also had a high
NLR showed the worst prognoses; they had poor OS rates
and experienced more rapid disease progression than those
without sarcopenia or a high NLR. We evaluated the prognostic
significance of pre-treatment sarcopenia and found it to be
less related to cancer treatment or chronic malnutrition due
to disease progression. These findings suggest that sarcopenia
combined with a high NLR reflects a very aggressive subgroup
of head and neck cancer when compared to malnutrition during
the course of the disease.
Some inflammatory mechanisms implicated in cancer-related
cachexia may be active in the earlier stages of disease and
can lead to muscle depletion long before the appearance of
extreme cancer cachexia. The direct impact of tumor-derived
factors on muscle tissue, which has been explored in preclinical
models that investigated the roles of tumor-induced systemic
inflammation and altered metabolism (17, 18), supports this
theory. Certain types of cancer can promote the up-regulation
of pro-inflammatory cytokines including interleukin-6 (IL-6),
tumor necrosis factor-α (TNFα), and interferon-γ, many of
which are anorexigenic and/or proteolytic. Tumor factors such
as the proteolysis-inducing factor are also involved in muscle
atrophy in cancer patients. Both cytokines and tumor factors
increase protein degradation through the ubiquitin-proteasome
pathway and depress protein synthesis via the phosphorylation of
eukaryotic inhibition factor 2α (19–21). Taken together, cancer-
related inflammation and sarcopenia accompanying this process
may reflect the aggressive nature of the tumor.
Although this study did not identify sarcopenia alone as an
independent prognostic factor, previous studies suggested that
sarcopenia may affect the survival, prognosis, and treatment
response in cancer patients independently. Sarcopenia was shown
to be associated with surgical mortality and OS in patients with
esophageal, breast, colon, lung, and gastrointestinal cancers (22–
25). Moreover, patients with sarcopenia were found to experience
a shorter time to progression (26). The same was shown to be
true for patients with head and neck cancer; Grossberg et al.
revealed that skeletal muscle depletion at presentation or after
treatment shortened OS and cancer-specific survival in patients
with head and neck squamous cell carcinoma and sarcopenia
(6). Further studies are required to identify patient subgroups in
whom sarcopenia may act as an independent prognostic factor.
G3 toxicities were observed with similar frequency in both
groups, although patients without sarcopenia experienced G3
oral mucositis more frequently than those with sarcopenia. Other
studies found that cancer-induced cachexia and its associated
pro-inflammatory cytokines may promote increased radiation-
related toxicities (27, 28). However, patients with sarcopenia
in our study were older and had a poorer performance status,
which might have caused physicians to opt for less aggressive
treatment. Nevertheless, these patients required more frequent
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RT interruptions than those in the non-sarcopenia group,
indicating that patients with sarcopenia have a lower tolerance
for treatment and treatment-related toxicities. This is consistent
with previous reports (26, 29), suggesting that classifying patients
according to the presence/absence of sarcopenia may provide a
rational basis for identifying patients who are at increased risk of
toxicity vs. those who may tolerate treatment well.
Patients with sarcopenia experienced more frequent RT
interruptions and subsequently showed inferior treatment
outcomes. Many previous studies suggested that interruption
or non-completion of RT is significantly associated with
patient survival and disease control (30). Known factors
affecting RT interruption include depression, anxiety, a lack
of appropriate information, pain, and other treatment-related
toxicities. Sarcopenia might also prompt patients to discontinue
treatment or request a de-intensified or decreased RT dose. Thus,
efforts should be made to provide intensive nutritional support,
and more education and support are needed to encourage
patients not to interrupt treatment (31).
Identifying patients with sarcopenia, especially when
accompanied by systemic inflammation, may be valuable for
identifying patients at higher risk for poor survival. Many
studies have suggested effective strategies to prevent and treat
muscle wasting in cancer patients. Specific dietary habits,
lifestyle modifications, and treatments that can prevent or delay
the negative effects of sarcopenia are recommended. Simple
nutritional support can increase muscle mass, and regular
exercise can help augment muscle strength (32, 33). Moreover,
medications that block the cytokines associated with muscle
atrophy signaling pathways (e.g., myostatin/activin, TNFα, and
IL-6) or agents that induce muscle hypertrophy signal (e.g.,
growth hormone agonist, anabolic steroids, and Grelin) may
be useful (34). Including these strategies in current anticancer
treatments can help extend the survival of cancer patients.
There are several limitations to this study. Because of its
retrospective nature, it was not always possible to evaluate all
variables and possible confounding factors in all patients. PET-
CT or abdominal CT were not retrievable for all subjects, and
we could only evaluate routine blood test results; however,
other inflammatory markers would likely have provided more
informative data. Treatment-related toxicities and tolerances
were evaluated retrospectively, causing some ambiguities and
missing data. Nevertheless, this study is one of the largest
analyses evaluating the prognostic significance of sarcopenia with
inflammation in patients with head and neck cancer who received
definitive CCRT. Intensive care and nutritional counseling to
increase their muscle mass and strength can be provided to the
subgroup of patients we identified to be at increased risk of
poorer outcomes.
CONCLUSION
We found that sarcopenia accompanied by systemic
inflammation at initial diagnosis was significantly associated
with inferior OS and PFS in patients undergoing definitive CCRT
for head and neck cancer. Additionally, patients with sarcopenia
required RT interruption more frequently and showed poorer
outcomes than those without sarcopenia. To increase treatment
tolerance and prevent RT interruption, patients should receive
intensive nutritional support and additional types of treatments
during CCRT.
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